Urotensin-II and UII-receptor expression and function in the rat adrenal cortex

International Journal of Molecular Medicine

Volumn 17, Issue 6, 2006, Pages 1111-1115

  Albertin, Giovanna ^a   Casale, Valentina ^a   Ziolkowska, Agnieszka ^b   Spinazzi, Raffaella ^a   Malendowicz, Ludwik K ^b   Rossi, Gian Paolo ^a   Nussdorfer, Gastone G ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Adrenal cortex; Glucocorticoid secretion; Palosuran; Rat; Urotensin receptor; Urotensin II; Urotensin receptor antagonists

Indexed keywords

1 (2 (4 BENZYL 4 HYDROXYPIPERIDIN 1 YL)ETHYL) 3 (2 METHYLQUINOLIN 4 YL)UREA; 1-(2-(4-BENZYL-4-HYDROXYPIPERIDIN-1-YL)ETHYL)-3-(2-METHYLQUINOLIN-4-YL)UREA; CORTICOTROPIN; DRUG DERIVATIVE; G PROTEIN COUPLED RECEPTOR; MESSENGER RNA; QUINOLINE DERIVATIVE; UREA; UROTENSIN; UROTENSIN II; UTS2R PROTEIN, RAT;

ADRENAL CORTEX; ANIMAL; ARTICLE; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; MALE; METABOLISM; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT;

ADRENAL CORTEX; ADRENOCORTICOTROPIC HORMONE; ANIMALS; CELLS, CULTURED; MALE; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UREA; UROTENSINS;

EID: 33745727515     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.17.6.1111     Document Type: Article

References (67)

1. Pearson D, Shively JE, Clark BR, Geschwind II, Barkley M, Nishioka RS and Bern HA: Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 77: 5021-5024, 1980.
2. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Ao Z, Coatney RW, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DWP, Ohlstein EH, Bergsma DJ and Douglas SA: Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401: 282-286, 1999.
3. Douglas SA and Ohlstein EH: Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 10: 229-237, 2000.
4. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH and Willette RN: Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131: 1262-1274, 2000.
5. Liu Q, Pong SS, Zeng Z, Zhang Q, Howard AD, Williams DL Jr, Davidoff M, Wang R, Austin CP, McDonald TP, Bai C, George SR, Evans JF and Caskey CT: Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 266: 174-178, 1999.
6. Mori M, Sugo T, Abe M, Shimomura Y, Kurihara M, Kitada C, Kikuchi K, Shintani Y, Kurokawa T, Onda H, Nishimura O and Fujino M: Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem Biophys Res Commun 265: 123-129, 1999.
7. Carotenuto A, Grieco P, Novellino E and Rovero P: Urotensin-II receptor peptide agonists. Med Res Rev 24: 577-588, 2004.
8. Kompa AR, Thomas WG, See F, Tzanidis A, Hannan RD and Krum H: Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides 25: 1783-1788, 2004.
9. Richards AM and Charles C: Urotensin II in the cardiovascular system. Peptides 25: 1795-1802, 2004.
10. Russell FD and Molenaar P: Cardiovascular actions of human urotensin II: considerations for hypertension. Naunyn Schmiedebergs Arch Pharmacol 369: 271-273, 2004.
11. Thanassoulis G, Huyhn T and Giaid A: Urotensin II and cardiovascular diseases. Peptides 25: 1789-1794, 2004.
12. Watson AMD and May CN: Urotensin II, a novel peptide in central and peripheral cardiovascular control. Peptides 25: 1759-1766, 2004.
13. Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, Kimura Y, Sasano H and Murakami O: Role of urotensin II in patients on dialysis. Lancet 358: 810-811, 2001.
14. Takahashi K, Totsune K, Murakami O, Arihara Z, Noshiro T, Hayashi Y and Shibahara S: Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II. Peptides 24: 301-306, 2003.
15. Tamura K, Okazaki M, Tamura M, Isozumi K, Tasaki H and Nakashima Y: Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. Life Sci 72: 1049-1060, 2003.
16. Maguire JJ, Kuc RE, Wiley KE, Kleinz MJ and Davenport AP: Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 25: 1767-1774, 2004.
17. Yoshimoto T, Matsushita M and Hirata Y: Role of urotensin II in peripheral tissue as an autocrine/paracrine growth factor. Peptides 25: 1775-1781, 2004.
18. Takahashi K, Totsune K, Murakami O and Shibahara S: Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells. Peptides 22: 1175-1179, 2001.
19. Maguire JJ and Davenport AP: Is the urotensin-II the new endothelin? Br J Pharmacol 137: 579-588, 2002.
20. Onan D, Hannan RD and Thomas WG: Urotensin-II: the old kid in town. Trends Endocrinol Metab 15: 175-182, 2004.
21. Nussdorfer GG, Rossi GP, Malendowicz LK and Mazzocchi G: Autocrine-paracrine endothelin system in the physiology and pathology of steroid secreting tissues. Pharmacol Rev 51: 403-438, 1999.
22. Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W, Hess P, Mathys B, Morrison K, Müller C, Müller C, Nayler O, Qiu C, Rey M, Scherz MW, Velker J, Weller T, Xi JF and Ziltener P: Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4- hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 311: 204-212, 2004.
23. Malendowicz LK, Spinazzi R, Tortorella C, Nussdorfer GG, Ziolkowska A and Rucinski M: Effects of leptin and leptin fragments on corticosterone secretion and growth of cultured rat adrenocortical cells. Int J Mol Med 14: 873-877, 2004.
24. 1]CER on the secretion and growth of cultured adrenocortical cells. Int J Mol Med 15: 411-415, 2005.
25. Mazzocchi G, Rossi GP, Neri G, Malendowicz LK, Albertin G and Nussdorfer GG: 11β-Hydroxysteroid dehydrogenase expression and activity in the human adrenal cortex. FASEB J 12: 1533-1539, 1998.
26. Albertin G, Carraro G, Petrelli L, Guidolin D, Neri G and Nussdorfer GG: Endothelin-1 and adrenomedullin enhance the growth of human adrenocortical carcinoma-derived SW-13 cell line by stimulating proliferation and inhibiting apoptosis. Int J Mol Med 15: 469-474, 2005.
27. Ziolkowska A, Rucinski M, Di Liddo R, Nussdorfer GG and Malendowicz LK: Expression of the beacon gene in the rat adrenal glands: direct inhibitory effect of beacon [47-73] on aldosterone secretion from dispersed adrenal zona glomerulosa cells. Int J Mol Med 13: 215-219, 2004.
28. Albertin G, Rucinski M, Carraro G, Forneris M, Andreis P, Malendowicz LK and Nussdorfer GG: Adrenomedullin and vascular endothelium growth factor genes are overexpressed in the regenerating rat adrenal cortex, and AM and VEGF reciprocally enhance their mRNA expression in cultured rat adrenocortical cells. Int J Mol Med 16: 431-435, 2005.
29. Albertin G, Carraro G and Nussdorfer GG: Human adrenomedullin gene silencing by short interfering RNAs: a preliminary study. Int J Mol Med 15: 579-583, 2005.
30. Andreis PG, Rucinski M, Neri G, Conconi MT, Petrelli L, Parnigotto PP, Malendowicz LK and Nussdorfer GG: Neuropeptides B and W enhance the growth of human adrenocortical carcinoma-derived NCI-H295 cells by exerting MAPK p42/p44-mediated proliferogenic and antiapoptotic effects. Int J Mol Med 16: 1021-1028, 2005.
31. Rucinski M, Andreis PG, Ziolkowska A, Nussdorfer GG and Malendowicz LK: Differential expression and function of beacon in the rat adrenal cortex and medulla. Int J Mol Med 16: 35-40, 2005.
32. Hochol A, Albertin G, Nussdorfer GG, Spinazzi R, Ziolkowska A, Rucinski M and Malendowicz LK: Effects of neuropeptides B and W on the secretion and growth of rat adrenocortical cells. Int J Mol Med 14: 843-847, 2004.
33. Ziolkowska A, Carraro G, Rebuffat P, Spinazzi R, Nussdorfer GG, Rucinski M and Malendowicz LK: Beacon[47-73] inhibits glucocorticoid secretion and growth of cultured rat and human adrenocortical cells. Int J Mol Med 14: 457-461, 2004.
34. Spinazzi R, Ziolkowska A, Neri G, Nowak M, Rebuffat P, Nussdorfer GG, Andreis PG and Malendowicz LK: Orexins modulate the growth of cultured rat adrenocortical cells, acting through type 1 and type 2 receptors coupled to the MAPK p42/ p44- and p38-dependent cascades. Int J Mol Med 15: 847-852, 2005.
35. Behm DJ, Herold CL, Ohlstein EH, Knight SD, Dhanak D and Douglas SA: Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val- Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Br J Pharmacol 137: 449-458, 2002.
36. Cheung BMY, Leung R, Man YB and Wong LYF: Plasma concentration of urotensin II is raised in hypertension. J Hypertens 22: 1341-1344, 2004.
37. Douglas SA, Tayara L, Ohlstein EH, Halawa N and Giaid A: Congestive heart failure and expression of myocardial urotensin II. Lancet 359: 1990-1997, 2002.
38. Ng LL, Loke I, O'Brien RJ, Squire IB and Davies JE: Plasma urotensin in human systolic heart failure. Circulation 106: 2877-2880, 2002.
39. Richards AM, Nichols MG, Lainchbury JG, Fisher S and Yandle TG: Plasma urotensin II in heart failure. Lancet 360: 545-546, 2002.
40. Russell FD, Meyers D, Galbraith AJ, Bett N, Toth I, Kearns P and Molenaar P: Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol 285: H1576-H1581, 2003.
41. Hassan GS, Douglas SA, Ohlstein EH and Giaid A: Expression of urotensin-II in human coronary atherosclerosis. Peptides 26: 2464-2472, 2005.
42. Zhou Y, Nagai R and Yamazaki T: Urotensin II induces hypertropic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett 508: 57-60, 2001.
43. Johns DG, Ao Z, Naselsky D, Herold CL, Sarov-Blat L, Maniscalco K, Steplewski K, Aiyar N and Douglas SA: Urotensin-II-mediated cardiomyocyte hypertrophy: the effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 370: 238-250, 2004.
44. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE and Krum H: Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93: 246-253, 2003.
45. Kedzierski RM and Yanagisawa M: Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol 41: 851-876, 2001.
46. Rossi GP, Seccia MT and Nussdorfer GG: Reciprocal regulation od endothelin-1 and nitric oxide: relevance in the physiology and pathology of the cardiovascular system Int Rev Cytol 209: 241-272, 2001.
47. Russell FD, Molenaar P and O'Brien DM: Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 132: 5-9, 2001.
48. Katano Y, Ishihata A, Aita T, Ogaki T and Horie T: Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur J Pharmacol 402: R5-R7, 2000.
49. Gendron G, Gobeil F Jr, Belanger S, Gagnon S, Regoli D, D'Orleans-Juste P: Urotensin II-induced hypotensive responses in Wistar-Kyoto (Wky) and spontaneously hypertensive (Shr) rats. Peptides 26: 1468-1474, 2005.
50. Belloni AS, Guidolin D, Ceretta S, Bova S and Nussdorfer GG: Acute effects of endothelins on endogenous adrenomedullin system in the rat heart: immunocytochemical and autoradiographic studies. Int J Mol Med 13: 669-674, 2004.
51. Lopez J and Martinez A: Cell and molecular biology of the multifunctional peptide adrenomedullin. Int Rev Cytol 221: 1-92, 2002.
52. Nagaya N, Mori H, Murakami S, Kangawa K and Kitamura S: Adrenomedullin: angiogenesis and gene therapy. Am J Physiol 288: R1432-R1437, 2005.
53. Nussdorfer GG: Proadrenomedullin-derived peptides in the paracrine control of the hypothalamo-pituitary-adrenal axis. Int Rev Cytol 206: 249-284, 2001.
54. Ziolkowska A, Tortorella C, Nussdorfer GG, Rucinski M, Majchrzak M and Malendowicz LK: Accumulation of steroidogenic acute regulatory protein mRNA, and decrease in the secretory and proliferative acrivity of rat adrenocortical cells in the presence of proteasome inhibitors. Int J Mol Med 17: 865-868, 2006.
55. Nussdorfer GG: Cytophysiology of the adrenal cortex. Int Rev Cytol 98: 1-405, 1986.
56. Nussdorfer GG: Paracrine control of adrenal cortical function by medullary chromaffin cells. Pharmacol Rev 48: 495-530, 1996.
57. Delarue C, Contesse V, Lenglet S, Sicard F, Perraudin V, Lefebvre H, Kodjo M, Leboulenger F, Yon L, Gallo-Payet N and Vaudry H: Role of neurotransmitters and neuropeptides in the regulation of the adrenal cortex. Rev Endocr Metab Disorders 2: 253-267, 2001.
58. Naruse M, Obana K, Naruse K, Yamaguchi H, Demura H, Inagami T and Shizume K: Atrial natriuretic polypeptide inhibits cortisol secretion as well as aldosterone secretion in vitro from human adrenal tissue. J Clin Endocrinol Metab 64: 10-16, 1987.
59. Hashiguchi T, Higuchi K, Ohashi M, Minamino N, Kangawa K, Matsuo H and Nawata H: Porcine brain natriuretic peptide: another modulator of bovine adrenocortical steroidogenesis. FEBS Lett 236: 455-461, 1988.
60. Nawata H, Ohashi M, Haji M, Takayanagi R, Higuchi K, Fujio N, Hashiguchi T, Ogo A, Nakao R, Ohnaka K and Nishi Y: Atrial and brain natriuretic peptide in adrenal steroidogenesis. J Steroid Biochem Mol Biol 40: 367-379, 1991.
61. Ganguly A: Atrial natriuretic peptide-induced inhibition of aldosterone secretion; a quest for mediator(s). Am J Physiol 263: E181-E194, 1992.
62. Mazzocchi G, Malendowicz LK, Andreis PG and Nussdorfer GG: Neurotensin inhibits the stimulatory effect of angiotensin-II and potassium on aldosterone secretion by rat zona glomerulosa cells. Exp Clin Endocrinol 97: 34-38, 1991.
63. Malendowicz LK, Nussdorfer GG, Hinson JP and Vinson GP: Evidence that endogenous neurotensin exerts a tonic inhibitory influence on adrenal zona glomerulosa growth and secretory activity in the rat. Med Sci Res 24: 189-190, 1996.
64. Bornstein SR, Uhlmann K, Haidan A, Ehrhart-Bornstein M and Scherbaum WA: Evidence for a novel peripheral action of leptin as a metabolic signal to the adrenal gland. Leptin inhibits cortisol release directly. Diabetes 46: 1235-1238, 1997.
65. Pralong FP, Roduit R, Waeber G, Castillo E, Mosimann F, Thorens B and Gaillard RC: Leptin inhibits directly glucocorticoid secretion by normal human and rat adrenal gland. Endocrinology 139: 4264-4268, 1998.
66. Glasow A and Bornstein SR: Leptin and the adrenal gland. Eur J Clin Invest 30: 39-45, 2000.
67. Ziolkowska A, Rucinski M, Di Liddo R, Nussdorfer GG and Malendowicz LK: Expression of the beacon gene in endocrine glands of the rat. Peptides 25: 133-137, 2004.